Are Analysts Bullish about Coherus BioSciences, Inc. (NASDAQ:CHRS) after last week?

October 2, 2018 - By Adrian Erickson

Coherus BioSciences, Inc. (NASDAQ:CHRS) LogoInvestors sentiment increased to 2.28 in Q2 2018. Its up 0.79, from 1.49 in 2018Q1. It improved, as 14 investors sold Coherus BioSciences, Inc. shares while 18 reduced holdings. 27 funds opened positions while 46 raised stakes. 57.78 million shares or 12.85% more from 51.20 million shares in 2018Q1 were reported.
Hanseatic Management Service has 0% invested in Coherus BioSciences, Inc. (NASDAQ:CHRS) for 189 shares. Thrivent Financial For Lutherans stated it has 58,137 shares or 0% of all its holdings. D E Shaw And Incorporated has invested 0% in Coherus BioSciences, Inc. (NASDAQ:CHRS). Quantbot Lp holds 5,162 shares or 0% of its portfolio. 4.14M were accumulated by Blackrock. Fmr Limited Com holds 0.01% or 6.90M shares. Marshall Wace Ltd Liability Partnership has 26,358 shares. Rhenman & Ptnrs Asset Management holds 0.5% or 350,000 shares. California State Teachers Retirement Sys accumulated 71,646 shares or 0% of the stock. Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% or 2,845 shares. Acuta Cap Prns Llc accumulated 345,000 shares or 0.86% of the stock. Stifel Financial holds 38,806 shares. New York-based Morgan Stanley has invested 0% in Coherus BioSciences, Inc. (NASDAQ:CHRS). Boston Advsrs Ltd Liability stated it has 29,515 shares. Dekabank Deutsche Girozentrale has 21,900 shares for 0% of their portfolio.

Coherus BioSciences, Inc. (NASDAQ:CHRS) Ratings Coverage

Among 2 analysts covering Coherus BioSciences (NASDAQ:CHRS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Coherus BioSciences had 2 analyst reports since May 14, 2018 according to SRatingsIntel. On Monday, May 14 the stock rating was maintained by Maxim Group with “Buy”. Below is a list of Coherus BioSciences, Inc. (NASDAQ:CHRS) latest ratings and price target changes.

28/08/2018 Broker: H.C. Wainwright Rating: Buy New Target: $28 Initiates Coverage On
14/05/2018 Broker: Maxim Group Old Rating: Buy New Rating: Buy Old Target: $18 New Target: $22 Maintain

The stock decreased 0.92% or $0.15 during the last trading session, reaching $16.11. About 289,002 shares traded. Coherus BioSciences, Inc. (NASDAQ:CHRS) has risen 44.53% since October 2, 2017 and is uptrending. It has outperformed by 28.91% the S&P500.

Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company has market cap of $1.09 billion. The companyÂ’s product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non–small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. It currently has negative earnings. The Company’s product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behçet's Disease, CrohnÂ’s Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.

More news for Coherus BioSciences, Inc. (NASDAQ:CHRS) were recently published by: Globenewswire.com, which released: “Coherus BioSciences Announces New Employment Inducement Grants” on September 21, 2018. Gurufocus.com‘s article titled: “Amgen’s Neulasta Has a New Competitor in Europe” and published on September 26, 2018 is yet another important article.

Coherus BioSciences, Inc. (NASDAQ:CHRS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>